Positive effects of ART26.12 were observed in a surgical rat model of osteoarthritis, in which either single or repeated oral ...

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, ...

By now, you’ve probably heard that seed oils are the nutritional villain du jour. A recent study takes a more measured, ...

The first selective fatty acid binding protein 5 (FABP5) inhibitor to enter clinical trials completed enrollment of its Phase I safety study in healthy volunteers. Data readout remains on track for ...

The research highlights ART26.12, Artelo’s orally active, small-molecule inhibitor of Fatty Acid Binding Protein 5 (FABP5), and its potential ability to treat psoriasis. Also Read: Why Is Hoth ...

Researchers found that linoleic acid activates a major cancer growth pathway by binding to FABP5, leading to increased tumor growth. Researchers found that linoleic acid activates a major cancer ...

"Future nutritional studies might consider stratifying patients on the basis of FABP5 expression and triple-negative status." Article continues below Last year, a study funded by the US government ...

Concept: TNBCs express the fatty acid binding protein FABP5, which senses ω-6 LA and promotes mTOR-Raptor complex function. Impact: This study highlights FABP5 as a functional link between dietary fat ...

In the study, published March 14 in Science, the researchers found that linoleic acid can activate a major growth pathway in tumour cells by binding to a protein called FABP5. Comparing breast ...